Join us on Tuesday, July 11^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by an educational grant from Gilead Sciences Inc.

Target Audience
This activity is intended for medical and radiation oncologists, nurses, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of higher-risk myelodysplastic syndromes.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the value of molecular testing for patients with myelodysplastic syndromes (MDS), and determine how various genetic alterations may affect MDS classification and risk assessment.
• Evaluate the importance of age, performance status, cytogenetic profile and other patient- and disease-related factors in the selection and sequencing of therapy for higher-risk MDS.
• Recognize the FDA approval of oral hypomethylating agent therapy for intermediate- and high-risk MDS, and identify patients for whom treatment with this novel approach may be appropriate.
• Describe the biological rationale for and available research findings with Bcl-2-targeted therapy for high-risk MDS, and appraise the role of this strategy in current and future clinical care.
• Assess the scientific justification for and published research findings with novel agents targeting CD47 in MDS to determine the potential clinical applicability of these approaches.
• Develop an understanding of the mechanisms of action of and available data with other investigational approaches for higher-risk MDS in order to prepare for their potential availability in routine practice.
• Implement a plan to manage the side effects associated with approved and investigational therapies for MDS to support quality of life and continuation of treatment.
• Recollect the designs of ongoing clinical trials for high-risk MDS, and counsel appropriate patients about the potential benefits of participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Garcia-Manero has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Sallman — Advisory Committee: AvenCell, bluebird bio, Bristol Myers Squibb, Intellia Therapeutics, Jasper Therapeutics Inc, Kite, A Gilead Company, Magenta Therapeutics, Nkarta Inc, Novartis, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Affimed GmbH, Gilead Sciences Inc, Incyte Corporation, Molecular Partners, Precigen Inc, Takeda Pharmaceuticals USA Inc, Zentalis Pharmaceuticals; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Nonrelevant Financial Relationship: Intellisphere Oncology Specialty Group.

SURVEY PARTICIPANTS — Uma Borate, MD, MS — Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AbbVie Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: Takeda Pharmaceuticals USA Inc. Andrew M Brunner, MD — Consulting Agreements: Acceleron Pharma, Agios Pharmaceuticals Inc, Bristol Myers Squibb, Gilead Sciences Inc, Keros Therapeutics, Novartis, Rigel Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc. Amy E DeZern, MD, MHS — Consulting Agreements: Apellis, Caribou Biosciences, Bristol Myers Squibb, Geron, Novartis, Regeneron Pharmaceuticals Inc, Sobi; Data and Safety Monitoring Board/Committee: Geron. Richard M Stone, MD — Advisory Board: AbbVie Inc, Actinium Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, AvenCell, Boston Pharmaceuticals, Bristol Myers Squibb, Celularity, CTI BioPharma Corp, Genentech, a member of the Roche Group, GSK, Hemavant, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Lava Therapeutics, Ligand Pharmaceuticals Incorporated, Novartis, Syros Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; AML Expert Council: GSK; Data and Safety Monitoring Board/Committee: Aptevo Therapeutics, Epizyme Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Focus Group: BerGenBio ASA; Grand Rounds: Jazz Pharmaceuticals Inc; Steering Committee: AbbVie Inc. Eunice S Wang, MD — Advisory Committee and Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, CTI BioPharma Corp, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Kura Oncology, Novartis, Rigel Pharmaceuticals Inc, SELLAS Life Sciences, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Gilead Sciences Inc; Speakers Bureau: Astellas, Kura Oncology, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by an educational grant from Gilead Sciences Inc.